Poll: How comfortable are you with including biosimilars in your treatment plans?

Poll

Vote in our most recent poll!

How comfortable are you with including biosimilars in your treatment plans?

A. Very excited to begin embracing biosimilars
B. Feeling comfortable exploring biosimilar options, though cautiously
C. Still hesitant, I need to learn more about biosimilars
D. With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans

RELATED: Introduction to biosimilars for AMD

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Jeffry Gerson, OD, FAAO, chats with Optometry Times about his talks about retina conditions at Vision Expo West
© 2025 MJH Life Sciences

All rights reserved.